Reckitt Benckiser Pharmaceuticals Inc. Announces FDA Approval of Two New Dosage Strengths of Suboxone Sublingual Film (C-III) for Maintenance Treatment of Opioid Dependence

RICHMOND, Va., Aug. 20, 2012 /PRNewswire/ — Reckitt Benckiser
Pharmaceuticals Inc. today announced the U.S. Food and Drug
Administration (FDA) approval of the 4 mg and 12 mg doses of
Suboxone® (buprenorphine and naloxone) sublingual… (Source: Drugs.com – Pharma News)